Human Movement and Sport Sciences, University of Rome "Foro Italico", 00135 Rome, Italy; Interuniversity Centre of Bioengineering of the Human Neuromusculoskeletal System, University of Rome "Foro Italico", 00135 Roma, Italy.
Department of Clinical, Internal Anesthesiology and Cardiovascular Sciences, "Sapienza" University of Rome, Rome, Italy.
Comput Methods Programs Biomed. 2024 Dec;257:108473. doi: 10.1016/j.cmpb.2024.108473. Epub 2024 Oct 28.
Right ventricular failure increases short-term mortality in the setting of acute myocardial infarction, cardiogenic shock, advanced left-sided heart failure and pulmonary arterial hypertension. Percutaneous and surgically implanted right ventricular assist devices (RVAD) have been investigated in different clinical settings. The use of the ProtekDuo™ is currently a promising approach due to its features such as groin-free approach leading to early mobilisation, easy percutaneous deployment, compatibility with different pumps and oxygenators, and adaptability to different configurations. The aim of this work was to simulate the behaviour of the TandemHeart™ pump applied "in series" and "in parallel" mode and the combination of TandemHeart™ and ProtekDuo™ cannula as RVAD using CARDIOSIM© software simulator platform.
To achieve our aim, two new modules have been implemented in the software. The first module simulated the TandemHeart™ pump in RVAD configuration, both as a right atrial-pulmonary arterial and a right ventricular-pulmonary arterial connection, driven by four different rotational speeds. The second module reproduced the behaviour of the ProtekDuo™ cannula plus TandemHeart™.
The effects induced on the main haemodynamic and energetic variables were analysed for both the right atrial-pulmonary arterial and right ventricular-pulmonary arterial configuration with different pump rotational speed and following Milrinone administration. The TandemHeart™ increased right ventricular end systolic volume by 10 %, larger increases were evident for higher speeds (6000 and 7500 rpm) and connections with 21-Fr inflow and 17-Fr outflow cannula, respectively. Both TandemHeart™ and ProtekDuo™ support increased left ventricular preload. When different RVAD settings were used, Milrinone therapy increased the left ventricular pressure-volume area and decreased the right pressure-volume area slightly. A reduction in oxygen consumption (demand) was observed with reduced right stroke work and pressure volume area and increased oxygen supply (coronary blood flow).
The outcome of our simulations confirms the effective haemodynamic assistance provided by the ProtekDuo™ as observed in the acute clinical setting. A simulation approach based on pressure-volume analysis combined with modified time-varying elastance and lumped-parameter modelling remains a suitable tool for clinical applications.
右心衰竭会增加急性心肌梗死、心源性休克、左心衰竭晚期和肺动脉高压患者的短期死亡率。经皮和植入式右心室辅助装置(RVAD)已在不同的临床环境中进行了研究。由于 ProtekDuo™ 具有无腹股沟入路、可早期活动、易于经皮植入、与不同的泵和氧合器兼容以及适应不同构型等特点,因此它的应用前景广阔。本研究旨在使用 CARDIOSIM©软件模拟平台模拟 TandemHeart™泵在串联和并联模式下的工作情况,并模拟 TandemHeart™泵和 ProtekDuo™ 导管作为 RVAD 的联合应用。
为了实现这一目标,我们在软件中实现了两个新模块。第一个模块模拟了 TandemHeart™泵在 RVAD 配置下的工作情况,分别模拟了右心房-肺动脉和右心室-肺动脉的连接,由四种不同的转速驱动。第二个模块再现了 ProtekDuo™导管与 TandemHeart™联合使用的情况。
我们分析了不同泵转速和米力农给药后,右心房-肺动脉和右心室-肺动脉两种构型对主要血流动力学和能量变量的影响。TandemHeart™可使右心室收缩末期容积增加 10%,在较高转速(6000 和 7500rpm)和使用 21-Fr 流入管和 17-Fr 流出管时,增加更为明显。TandemHeart™和 ProtekDuo™均可增加左心室前负荷。当使用不同的 RVAD 设置时,米力农治疗可增加左心室压力-容积面积,并略微降低右心室压力-容积面积。由于右心室每搏功和压力-容积面积减少,以及冠状血流增加,氧耗(需求)减少。
我们的模拟结果证实了 ProtekDuo™在急性临床环境中提供的有效血流动力学辅助作用。基于压力-容积分析并结合改良时变弹性和集总参数模型的模拟方法仍然是一种适用于临床应用的工具。